Xtant Medical is a leading player in the regenerative medicine products and medical devices market, catering to both domestic and international markets. The company, founded in 2006, focuses on providing specialized solutions for orthopedic and neurological surgeons. Its offerings include orthobiologics, implants, instrumentation, tissue grafts, and biologics that promote healing following cranial, foot, and ankle surgeries. Xtant's expertise in both biologic and non-biologic surgical technologies positions it strongly in the global neurological and orthopedic surgery markets. The company's recent $17.00M post-IPO debt investment on March 7, 2024, by MidCap Financial, reflects confidence in its growth trajectory. Xtant's commitment to innovation and its ability to address the specialized needs of surgeons make it a compelling player in the Health Care and Manufacturing industries. For further information, please visit xtantmedical.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $17.00M | 1 |
|
07 Mar 2024 |
| Post-IPO Equity | $15.00M | - | 03 Jul 2023 | |
| Post-IPO Equity | $9.75M | 1 | Stavros Vizirgianakis | 24 Aug 2022 |
| Post-IPO Debt | $20.00M | 1 |
|
06 May 2021 |
| Post-IPO Equity | $20.00M | - | 22 Feb 2021 |
No recent news or press coverage available for Xtant Medical.
We care about your data, and we'd love to use cookies make your experience better.
